Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pamidronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 11/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamidronic Acid SCHEMBL4260287 | 1.00 | FDPS (0.62) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL18751 | 0.98 | FDPS (0.64) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL570526 | 0.89 | FDPS (0.78) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL2641229 | 0.83 | FDPS (0.68) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL570525 | 0.80 | FDPS (0.71) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL3110183 | 0.79 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL3388 | 0.79 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL204535 | 0.79 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL536412 | 0.79 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5973704 | 0.79 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513010-B2 | Dendritic cells pulsed with a bisphosphonate | MEDINET CO. LTD. (JP) | 2013-08-20 | — | — | US | claimed |
| US-11633457-B2 | Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use | BOISE STATE UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| US-20200323960-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ONCOSTATIN M (OSM) ANTAGONIST DERIVATIVES AND METHODS OF USE | BOISE STATE UNIVERSITY | 2020-10-15 | — | — | US | disclosed |
| WO-2019156566-A1 | BISPECIFIC MOLECULES COMPRISING GAMMA-DELTA TCR AND T-CELL OR NK CELL BINDING DOMAIN | UMC UTRECHT HOLDING B.V. (NL) | 2019-08-15 | — | — | WO | disclosed |
| US-10286070-B2 | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders | BOISE STATE UNIVERSITY (US) | 2019-05-14 | — | — | US | disclosed |
| US-20170240859-A1 | METHOD FOR PRODUCING GAMMA DELTA T CELLS, AND PHARMACEUTICAL THEREOF | ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE (JP) | 2017-08-24 | — | — | US | disclosed |
| EP-3208329-A1 | METHOD FOR PRODUCING GAMMA-DELTA T CELLS, AND PHARMACEUTICAL | St. Marianna University School of Medicine (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-20170196973-A1 | ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS | BOISE STATE UNIVERSITY (US) | 2017-07-13 | — | — | US | disclosed |
| US-9550828-B2 | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders | BOISE STATE UNIVERSITY (US) | 2017-01-24 | — | — | US | disclosed |
| CN-103551567-B | Surface modification method for cerium nano-particles | UNIV PLA 3RD MILITARY MEDICAL | 2015-06-17 | — | — | CN | disclosed |
| WO-2007081879-A2 | METHODS FOR PREVENTING AND TREATING CANCER METASTASIS AND BONE LOSS ASSOCIATED WITH CANCER METASTASIS | NOVARTIS AG (CH) | 2007-07-19 | — | — | WO | disclosed |
| EP-1788078-A1 | DENTRITIC CELL DRUG CONTAINING THE DENTRITIC CELL, THERAPEUTIC METHOD USING THE DENTRITIC CELL AND METHOD OF CULTURING GAMMA DELTA T CELL | Medinet., Co. Ltd. (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-20050182030-A1 | Antitumor, anticancer agents; osteoporosis; bone disorders; Paget's disorders; solution is provided in a sealed non-reactive plastic container of polypropylene, ABS, polyethylene, PVC, polycycloolefin; injectable, sterile, ready to use, pyrogen-free solution | AMERICAN PHARMACEUTICAL PARTNERS, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1390044-A4 | INJECTABLE PAMIDRONATE DISODIUM | SICOR INC (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040147486-A1 | Liquid injectable formulation of disodium pamidronate | American Pharmaceutical Partners | 2004-07-29 | — | — | US | disclosed |
| US-6709674-B2 | PACKAGED LIQUID COMPOSITION OF A SUGAR AND A PAMIDRONATE ALKALINE SALT IN A SEALED STORAGE VESSEL HAVING AN INNER SURFACE WHICH IS NON-REACTIVE WITH THE PAMIDRONATE ALKALINE SALT COMPOSITION. | GENSIA SICOR PHARMACEUTICALS, INC. | 2004-03-23 | — | — | US | disclosed |
| EP-1390044-A1 | INJECTABLE PAMIDRONATE DISODIUM | Sicor Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030069211-A1 | Injectable pamidronate disodium | GENSIA SICOR PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002089768-A1 | LIQUID INJECTABLE FORMULATION OF DISODIUM PAMIDRONATE | PHARMACEUTICAL PARTNERS OF CANADA INC. (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002087592-A1 | INJECTABLE PAMIDRONATE DISODIUM | SICOR INC. (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196973-A1 | ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS | IL6, OGFRL1, OGFR | FDPS 4781/4885PDE3A 3853/4885LMNA 3338/4885 |
| US-20200323960-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ONCOSTATIN M (OSM) ANTAGONIST DERIVATIVES AND METHODS OF USE | OGFR, OGFRL1, ELAVL1 | FDPS 4793/4885PDE3A 2815/4885LMNA 2391/4885 |
| US-20040147486-A1 | Liquid injectable formulation of disodium pamidronate | SOST, PHPT1, PTH1R | FDPS 1943/4885PDE3A 1400/4885LMNA 2768/4885 |
| US-20050182030-A1 | Antitumor, anticancer agents; osteoporosis; bone disorders; Paget's disorders; solution is provided in a sealed non-reactive plastic container of polypropylene, ABS, polyethylene, PVC, polycycloolefin; injectable, sterile, ready to use, pyrogen-free solution | SOST, PHPT1, PIK3CA | FDPS 1531/4885PDE3A 2933/4885LMNA 1945/4885 |
| US-10286070-B2 | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders | IL6, OGFRL1, OGFR | FDPS 4781/4885PDE3A 3853/4885LMNA 3338/4885 |
| US-20170240859-A1 | METHOD FOR PRODUCING GAMMA DELTA T CELLS, AND PHARMACEUTICAL THEREOF | CD4, IL2RA, CD2 | FDPS 4159/4885PDE3A 4842/4885LMNA 3802/4885 |
| US-11633457-B2 | Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use | OGFR, OGFRL1, ELAVL1 | FDPS 4793/4885PDE3A 2815/4885LMNA 2391/4885 |
| US-20030069211-A1 | Injectable pamidronate disodium | SLC20A1, TMEM205, PHOSPHO1 | FDPS 957/4885PDE3A 753/4885LMNA 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.